- Home
- ACM vs RPRX Comparison
ACM vs RPRX Comparison
Compare ACM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- RPRX
- Stock Information
- Founded
- ACM 1980
- RPRX 1996
- Country
- ACM United States
- RPRX United States
- Employees
- ACM N/A
- RPRX N/A
- Industry
- ACM Military/Government/Technical
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACM Consumer Discretionary
- RPRX Health Care
- Exchange
- ACM Nasdaq
- RPRX Nasdaq
- Market Cap
- ACM 12.8B
- RPRX 14.4B
- IPO Year
- ACM 2007
- RPRX 2020
- Fundamental
- Price
- ACM $92.90
- RPRX $32.84
- Analyst Decision
- ACM Strong Buy
- RPRX Strong Buy
- Analyst Count
- ACM 8
- RPRX 5
- Target Price
- ACM $120.38
- RPRX $41.60
- AVG Volume (30 Days)
- ACM 1.1M
- RPRX 4.7M
- Earning Date
- ACM 05-05-2025
- RPRX 05-08-2025
- Dividend Yield
- ACM 1.10%
- RPRX 2.68%
- EPS Growth
- ACM 685.21
- RPRX N/A
- EPS
- ACM 3.50
- RPRX 1.91
- Revenue
- ACM $16,219,730,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- ACM $6.71
- RPRX $33.46
- Revenue Next Year
- ACM $5.56
- RPRX $4.44
- P/E Ratio
- ACM $27.01
- RPRX $17.17
- Revenue Growth
- ACM 8.89
- RPRX N/A
- 52 Week Low
- ACM $82.23
- RPRX $24.05
- 52 Week High
- ACM $118.56
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- ACM 36.66
- RPRX 54.55
- Support Level
- ACM $94.31
- RPRX $33.06
- Resistance Level
- ACM $97.99
- RPRX $34.10
- Average True Range (ATR)
- ACM 2.88
- RPRX 0.67
- MACD
- ACM -0.05
- RPRX -0.25
- Stochastic Oscillator
- ACM 14.34
- RPRX 38.64
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $14.4 billion in sales and $847 million in adjusted operating income in fiscal 2023.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.